Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018033291 - T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME

Publication Number WO/2018/033291
Publication Date 22.02.2018
International Application No. PCT/EP2017/066630
International Filing Date 04.07.2017
IPC
C07K 14/725 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
C07K 14/78 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
Applicants
  • IMMATICS BIOTECHNOLOGIES GMBH [DE]/[DE]
Inventors
  • ALTEN, Leonie
  • MAURER, Dominik
  • WALTER, Steffen
  • BUNK, Sebastian
Agents
  • KRAUSS, Jan B.
Priority Data
10 2016 115 246.317.08.2016DE
62/376,05917.08.2016US
62/376,63218.08.2016US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
(FR) RÉCEPTEURS DE LYMPHOCYTES T ET THÉRAPIE IMMUNITAIRE LES UTILISANT
Abstract
(EN) The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
(FR) La présente invention concerne des constructions de reconnaissance d'antigènes contre des antigènes COL6A3. L'invention concerne en particulier de nouvelles molécules basées sur le récepteur des lymphocytes T (TCR) qui sont sélectifs et spécifiques pour l'antigène exprimé par la tumeur COL6A3. Le TCR de l'invention, et les fragments de liaison à l'antigène COL6A3 dérivés de celui-ci, sont utiles pour le diagnostic, le traitement et la prévention de maladies cancéreuses exprimant COL6A3. L'invention concerne en outre des acides nucléiques codant pour les constructions de reconnaissance d'antigènes de l'invention, des vecteurs comprenant ces acides nucléiques, des cellules recombinantes exprimant les constructions de reconnaissance d'antigènes et des compositions pharmaceutiques comprenant les composés de l'invention.
Related patent documents
TH1901000927This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
CRCR2019-000095This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
UAa201900959This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau